A Randomized, Double-blind, 2x2 Cross-over Euglycemic Clamp Study in Two Parallel Cohorts to Compare the Pharmacodynamic and Pharmacokinetic Properties of 0.4 and 0.6 U/kg/day Insulin Glargine (Toujeo) with the Same Dose Levels of Insulin Degludec (Tresiba) in Steady State After 8 Days Multiple Dosing Regimen in Patients with Diabetes Mellitus Type 1

Trial Profile

A Randomized, Double-blind, 2x2 Cross-over Euglycemic Clamp Study in Two Parallel Cohorts to Compare the Pharmacodynamic and Pharmacokinetic Properties of 0.4 and 0.6 U/kg/day Insulin Glargine (Toujeo) with the Same Dose Levels of Insulin Degludec (Tresiba) in Steady State After 8 Days Multiple Dosing Regimen in Patients with Diabetes Mellitus Type 1

Completed
Phase of Trial: Phase IV

Latest Information Update: 11 Nov 2016

At a glance

  • Drugs Insulin glargine (Primary) ; Insulin degludec
  • Indications Type 1 diabetes mellitus
  • Focus Pharmacodynamics
  • Sponsors Sanofi
  • Most Recent Events

    • 11 Nov 2016 Results published in a Sanofi media release.
    • 12 Oct 2016 Status changed from recruiting to completed.
    • 15 Sep 2016 Results published in the Sanofi Media Release
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top